An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema

Journal of Dermatological Treatment

Volumn 14, Issue 3, 2003, Pages 136-140

  Thelmo, M C ^a   Lang, Wei ^a   Brooke, E ^a   Osborne, B E ^a   McCarty, M A ^a   Jorizzo, J L ^a   Fleischer Jr , Alan B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Hand and foot eczema; Tacrolimus; Topical corticosteroids

Indexed keywords

CORTICOSTEROID; EMOLLIENT AGENT; MOMETASONE FUROATE; TACROLIMUS;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ERYTHEMA; FEMALE; FOLLOW UP; FOOT DISEASE; HAND ECZEMA; HUMAN; LONG TERM CARE; MALE; OINTMENT; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN INDURATION; SYMPTOM; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; ECZEMA; FEMALE; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; STATISTICS, NONPARAMETRIC; TACROLIMUS; TREATMENT OUTCOME;

EID: 0141920529     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.1080/09546630310009491     Document Type: Article

References (30)

1. nd Edition. Boca Raton (FL): CRC Press; (2000) pp. 15-23.
2. nd Edition. Boca Raton (FL): CRC Press; (2000) pp. 1-13.
3. nd Edition. Boca Raton (FL): CRC Press; (2000) pp. 27-41.
4. Sidbury R, Hanifin JM, Old, new, and emerging therapies for atopic dermatitis. Dermatol Clin (2000) 38: 1-11.
5. Smith EW, Four decades of topical corticosteroid assessment. Curr Probl Dermatol (1995) 22: 124-31.
6. Vein NK, Iholm Larsen P, Thestrup-Pedersen K, Schou G, Long-term intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol (1999) 140: 882-6.
7. Fleischer AB Jr, Treatment of atopic dermatitis: role of tacrolimus ointment as a topical noncorticosteroidal therapy. J Allergy Clin Immunol (1999) 104(3): S126-130.
8. Goto T, Kino T, Hatanaka M et al, FK 506: historical perspectives. Transplant Proc (1991) 23: 2713-2717.
9. Lawrence ID, Tacrolimus (FK506): experience in dermatology. Dermatol Ther (1998) 5: 74-84.
10. Cheer SM, Plosker G, Tacrolimus ointment: a review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol (2001) 2: 389-406.
11. Ruzicka T, Reitamo S, Bieber T, Tacrolimus ointment for atopic dermatitis. N Engl J Med (1998) 339: 1788-1789.
12. Reitamo S, Rissanen J, Remitz A et al, Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol (1998) 111: 396-398.
13. Kang S, Lucky AW, Pariser D et al, Tacrolimus ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol (2001) 44(suppl): S58-64.
14. Reitamo S, Wollenberg A, Schsöpf E et al, Safety and efficacy of one year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol (2000) 136: 999-1006.
15. Paller A, Eichenfield LF, Leung DYM et al, Tacrolimus ointment Study Group. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol (2001) 44(suppl): S47-57.
16. Hanifin JM, Ling MR, Langley R et al, Tacrolimus ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I. Efficacy. J Am Acad Dermatol (2001) 44(suppl): S28-38.
17. Soter NA, Fleischer AB Jr, Webster GF et al, Tacrolimus ointment Study Group. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II. Safety. J Am Acad Dermatol (2001) 44(suppl): 839-46.
18. Schnopp C, Remling R, Möhrenschlager M et al, Topical tacrolimus (FK506) and mometasone furoate in treatment of dyshidrotic palmar eczema: a randomized, observer-blinded trial. J Am Acad Dermatol (2002) 46: 73-77.
19. Bucks D, Guy R, Maibach HI, Effects of occlusion. In: Bronaugh RI, Maibach HI, (eds.) In vitro percutaneous absorption: Principles, Fundamentals, and Applications. Boca Raton (FL): CRC Press; (1991) pp. 85-114.
20. rd ed. New York: Dekker; (1999) pp. 81-105.
21. Scholtz JR, Topical therapy of psoriasis with fluocinolone acetonide. Arch Dermatol (1961) 84: 1029-1030.
22. Sulzberger MB, Witten VH, Thin pliable plastic films in topical dermatological therapy. Arch Dermatol (1961) 84: 1027-1028.
23. McKenzie AW, Percutaneous absorption of steroids. Arch Dermatol (1962) 86: 91-94.
24. McKenzie AW, Stoughton RB, Method for comparing percutaneous absorption of steroids. Arch Dermatol (1962) 86: 88-90.
25. Kaidbey KH, Petrozzi JW, Kligman AM, Topical colchicine therapy for recalcitrant psoriasis. Arch Dermatol (1975) 111: 33-36.
26. Treffel P, Muret P, Muret-D'Aniello P et al, Effect of occlusion on in vitro percutaneous absorption of two compounds with different physicochemical properties. Skin Pharmacol (1992) 5: 108-113.
27. Bucks DA, McMaster JR, Maibach HI, Guy RH, Bioavailability of topically administered steroids: a 'mass balance' technique. J Invest Dermatol (1988) 91: 29-33.
28. 14C] parathion in vivo in pigs. Toxicol Appl Pharmacol (1993) 122: 131-138.
29. 14C hydrocortisone through normal skin: the effect of stripping and occlusion. Arch Dermatol (1965) 91: 661-666.
30. Ryatt KS, Stevenson JM, Maibach HI, Guy RH, Pharmacodynamic measurement of percutaneous penetration enhancement in vivo. J Pharm Sci (1986) 75: 374-377.